You Position: Home > Paper

Nuclear-targeted therapy of nerve growth factor conjugated with 125I for human glioma U251 cells

( views:149, downloads:0 )
Author:
No author available
Journal Title:
NEURAL REGENERATION RESEARCH
Issue:
34
DOI:
10.3969/j.issn.1673-5374.2011.34.008
Key Word:
nuclear-targeted therapy;nerve growth factor;125I;glioma;conjugate;cell cycle arrest

Abstract: The present study investigated the nuclear transportation phenomenon of 125I-nerve growth factor (NGF) and the DNA-damaging changes to U251 cells using microautoradiography and single cell electrophoresis. The results showed that 125I-NGF inhibited the survival of p53 mutant U251 human glioma cell/tumor and enhanced the therapeutic effectiveness of vincristine in in vivo and in vitro models. In vitro experiments showed 125I-NGF was transported into the nucleus and damaged the DNA in U251 cells. Moreover, 125I-NGF locked the U251 cells in the G2 phase. Further investigation showed that 125I-NGF decreased cyclin B1 protein levels in a dose dependent manner, but the level of cyclin B1 mRNA expression remained unchanged. 125I-NGF increased phosphorylated Chk1, Chk2 and Cdc25c protein levels in U251 cells, but did not influence p53 and p21 protein expression. Moreover, 125I-NGF and vincristine exhibited synergistic effects on reducing cyclin B1 protein levels. These results indicate that 125I-NGF can provide anti-tumor effects by activating the ATM and ATR pathways through DNA damage.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn